Share on StockTwits

Eleven Biotherapeutics (NASDAQ:EBIO) major shareholder Jafco Super V3 Investment Limi sold 2,000 shares of the stock on the open market in a transaction dated Thursday, August 14th. The stock was sold at an average price of $11.75, for a total transaction of $23,500.00. Following the completion of the sale, the insider now directly owns 2,125,291 shares in the company, valued at approximately $24,972,169. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Eleven Biotherapeutics (NASDAQ:EBIO) traded up 0.59% during mid-day trading on Friday, hitting $11.91. The stock had a trading volume of 40,581 shares. Eleven Biotherapeutics has a 52 week low of $9.502 and a 52 week high of $19.333. The stock’s 50-day moving average is $12.08 and its 200-day moving average is $13.01. The company’s market cap is $183.3 million.

Eleven Biotherapeutics (NASDAQ:EBIO) last announced its earnings results on Wednesday, August 13th. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.47) by $0.04. On average, analysts predict that Eleven Biotherapeutics will post $-1.84 earnings per share for the current fiscal year.

Eleven Biotherapeutics, Inc, is a United States-based company, which develops protein-based biotherapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.